Engaging with multiple influencers – Payers, Patients and Prescribers, equally, has never been so important. Without doing so pharma runs the risk of not getting innovative and costly medication, to the patients.
As we’re dedicating more and more time to the shifting dynamics of stakeholder groups and how we engage with them. It’s essential that we change to a new multi-stakeholder approach, or we run the risk of falling behind. Access your copy here: https://goo.gl/UHZw6W
Our latest whitepaper “Balancing payers, patients and physicians: An integrated multi-stakeholder approach” features key insights from, Actelion, Pfizer, Bayer, Otsuka
Pharmaceuticals, VClinBio and Salesforce and discusses:
• How we can adapt an outdated commercial model to encompass enhanced cross-functional activities, and face the challenges of the industry with a new multi-stakeholder model
• The diminishing influence of the physician in healthcare decision-making, and how companies are increasingly seeing HCP’s as collaborators in patient care
• The changing demands of payers, and how as economic pressures increase their position becomes more influential to patient’s access to medication
Interested? Download your copy here: https://goo.gl/UHZw6W
Any questions, ask Giselle Quartin: gquartin@eyeforpharma.com